MDMA
CBSA busts 3.3 tonnes of chemicals used to manufacture MDMA
When ingested, 1,4-butanediol produces an effect that is not unlike that of Gamma-Hydroxybutyrate (GHB)
The post CBSA busts 3.3 tonnes of chemicals used…
The Canadian Border Services Agency (CBSA) busted a cargo of chemicals used to manufacture MDMA and other substances used for assault.
The agency announced the bust on Thursday but the crime happened between June and July this year at the Toronto Pearson International Airport Commercial Operations District. Agents intercepted over 3.3 tonnes of PMK ethyl glycidate to make MDMA and 1,4-butanediol arriving from Asia which were found in multiple separate shipments.
When ingested, 1,4-butanediol produces an effect that is not unlike that of gamma-hydroxybutyrate (GHB).
The agency said the drugs are used to manufacture MDMA, which is currently medically legal in Australia and several countries have clinical trials for its potential to help treat some mental disorders. However, the other substance was referred to as a drug used to commit physical and sexual assault. The drug affects the central nervous system and causes changes in mood, awareness and behavior.
One package of PMK ethyl glycidate. Photo by Canada Border Services Agency
Read more: Do not take your pot over the border: CBSA
Read more: Canadian border services seize 140-kilogram meth cargo thanks to Kiwi authorities
“Our officers continue to demonstrate their unwavering commitment to the safety and security of Canadians. Officer diligence prevented these precursor chemicals from being manufactured into harmful drugs and potentially impacting our communities,” Regional director general, CBSA Greater Toronto Area Region said in a statement.
The post CBSA busts 3.3 tonnes of chemicals used to manufacture MDMA appeared first on Mugglehead Magazine.
mdma
-
Psychedelics1 week agoMindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
-
Psychedelics1 week agoCompass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
-
Psychedelics1 week agoReunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
-
Psychedelics1 week ago
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
-
Psilocybin6 days agoThe Psychedelic Scene in Oaxaca, Mexico
-
Psychedelics1 week ago
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
-
Ketamine1 week ago
What marijuana reclassification could mean for health treatments
-
Psychedelics1 week ago
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
